There are efforts to improve the diagnosis and discovery of dx biomarkers, including the United States Food and Drug Administration (FDA)-approved Progensa assay (PCA3 (PCa gene 3) and PSA) and STHLM3 (Stockholm-3), which is currently being validated [7,8,9]. This evidence concerns the gene KLK3 and posterior cortical atrophy.